CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing ...
A sales partner offered a ray of hope that this company couldn't for itself.
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...
Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter ...
GA, UNITED STATES, February 4, 2026 / EINPresswire.com / — Researchers have developed a new biomimetic nanocomposite (mPDA-Cas9) for treating triple-negative breast cancer ( TNBC) by combining ...
Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru crafted a bespoke treatment that has successfully corrected the genetic ...
Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple ...
9don MSN
Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline
CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an ...
Oceanic ecosystems are increasingly threatened by global warming, which causes coral bleaching, species migration and, ...
Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after ...
4d
New Jersey man says CRISPR treatment for sickle cell disease changed his life: "It totally worked"
Austin Louis, 20, says the CRISPR treatment he received at the Children's Hospital of Philadelphia for sickle cell disease ...
Researchers developed a CRISPR-based system that spreads through bacterial populations to disable antibiotic resistance genes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results